Stephen Hanauer to Humans
This is a "connection" page, showing publications Stephen Hanauer has written about Humans.
Connection Strength
3.502
-
The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease. Expert Rev Gastroenterol Hepatol. 2025 Jul; 19(7):725-743.
Score: 0.030
-
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).
Score: 0.030
-
Corticosteroid Use in Randomized Clinical Trials of Biologics and Small Molecules in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2025 May 12; 31(5):1430-1440.
Score: 0.030
-
Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Rev Clin Immunol. 2025 Apr; 21(4):461-472.
Score: 0.029
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
Score: 0.028
-
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
Score: 0.027
-
EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way? Clin Gastroenterol Hepatol. 2024 Jul; 22(7):1377-1378.
Score: 0.027
-
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
Score: 0.026
-
Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. Inflamm Bowel Dis. 2023 05 02; 29(5):675-683.
Score: 0.026
-
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. Immunotherapy. 2022 12; 14(17):1353-1359.
Score: 0.025
-
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151.
Score: 0.025
-
COVID-19 and Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023 03; 52(1):103-113.
Score: 0.025
-
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflamm Bowel Dis. 2022 07 01; 28(7):1012-1018.
Score: 0.025
-
Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719.
Score: 0.024
-
A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2022 May; 16(5):411-423.
Score: 0.024
-
Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
Score: 0.023
-
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
Score: 0.023
-
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
Score: 0.023
-
Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep. 2021 Aug 02; 23(9):16.
Score: 0.023
-
Which Diet for Crohn's Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond. Gastroenterology. 2021 09; 161(3):798-800.
Score: 0.023
-
Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2020 11 19; 26(12):1808-1818.
Score: 0.022
-
Executive Summary of 'Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States'. Am J Gastroenterol. 2020 09; 115(9):1362-1366.
Score: 0.022
-
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305.
Score: 0.022
-
Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779.
Score: 0.021
-
Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020 02; 115(2):202-210.
Score: 0.021
-
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
Score: 0.021
-
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233.
Score: 0.020
-
Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 08 20; 25(9):1577-1585.
Score: 0.020
-
Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 08 20; 25(9):e114.
Score: 0.020
-
Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
Score: 0.020
-
More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 06 18; 25(7):1271-1276.
Score: 0.020
-
Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535.
Score: 0.019
-
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147.
Score: 0.019
-
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
Score: 0.019
-
A Never Ending STORI. Clin Gastroenterol Hepatol. 2018 07; 16(7):1034-1036.
Score: 0.018
-
Targeting Crohn's disease. Lancet. 2017 12 23; 390(10114):2742-2744.
Score: 0.018
-
Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607.
Score: 0.017
-
Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. Lancet. 2017 04 29; 389(10080):1671-1672.
Score: 0.017
-
Vitamin D Levels and Outcomes in Inflammatory Bowel Disease-Which is the Chicken and Which is the Egg? Clin Gastroenterol Hepatol. 2017 02; 15(2):247-248.
Score: 0.017
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
Score: 0.016
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
Score: 0.016
-
Oral or Topical 5-ASA in Ulcerative Colitis. Dig Dis. 2016; 34(1-2):122-4.
Score: 0.016
-
Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):A29-30.
Score: 0.016
-
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
Score: 0.015
-
Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5.
Score: 0.015
-
ACG presidential introduction. Am J Gastroenterol. 2015 Jan; 110(1):4-5.
Score: 0.015
-
The Holy Grail, or only half way there? Gastroenterology. 2015 Jan; 148(1):8-10.
Score: 0.014
-
Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
Score: 0.014
-
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5.
Score: 0.014
-
Still in pursuit. Gastroenterology. 2014 Jan; 146(1):13-5.
Score: 0.014
-
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75.
Score: 0.013
-
Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2.
Score: 0.013
-
Dissecting diverticulosis database dilemmas. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1525-6.
Score: 0.013
-
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63.
Score: 0.013
-
Reassessing the risks and benefits of thiopurines in Crohn's disease. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):395-7.
Score: 0.013
-
In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3.
Score: 0.013
-
Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2.
Score: 0.013
-
Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4.
Score: 0.013
-
Reply to Dr Kountouras et al.'s letter. J Crohns Colitis. 2013 Jul; 7(6):515.
Score: 0.012
-
In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7.
Score: 0.012
-
What to take from TREAT? Am J Gastroenterol. 2012 Sep; 107(9):1423-5.
Score: 0.012
-
Association between higher predicted serum vitamin D levels and reduced incidence of inflammatory bowel diseases. Gastroenterology. 2012 Sep; 143(3):e28.
Score: 0.012
-
Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3.
Score: 0.012
-
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
Score: 0.012
-
Commentary: pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012 Jul; 36(2):199-200; discussion 200.
Score: 0.012
-
Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5.
Score: 0.012
-
Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301.
Score: 0.012
-
Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
Score: 0.012
-
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4.
Score: 0.012
-
Can we treat ulcerative colitis with nutritional supplements? Aliment Pharmacol Ther. 2012 Feb; 35(4):485; author reply 486-7.
Score: 0.012
-
Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
Score: 0.012
-
Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85.
Score: 0.012
-
Calcineurin inhibition in severe ulcerative colitis: lost in translation? Inflamm Bowel Dis. 2012 May; 18(5):809-11.
Score: 0.012
-
Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18.
Score: 0.011
-
Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
Score: 0.011
-
Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011 Nov; 17(11):2366-91.
Score: 0.011
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
Score: 0.011
-
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
Score: 0.011
-
Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011 Feb; 5(1):48-53.
Score: 0.011
-
The role of biologics in ulcerative colitis. Dig Dis. 2010; 28(3):497-500.
Score: 0.011
-
Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500.
Score: 0.011
-
Ashes to ashes. Nat Rev Gastroenterol Hepatol. 2010 Jun; 7(6):299.
Score: 0.011
-
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
Score: 0.011
-
Penultimate. Nat Rev Gastroenterol Hepatol. 2010 May; 7(5):237.
Score: 0.011
-
Another vacation, another medical 'crisis'. Nat Rev Gastroenterol Hepatol. 2010 Apr; 7(4):179.
Score: 0.010
-
Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20.
Score: 0.010
-
The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):63-4.
Score: 0.010
-
A poor view from specialty silos. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7(1):1-2.
Score: 0.010
-
Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503.
Score: 0.010
-
Indecent exposures. Nat Rev Gastroenterol Hepatol. 2009 Dec; 6(12):685.
Score: 0.010
-
Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27(4):536-41.
Score: 0.010
-
Great (cultural) expectations. Nat Rev Gastroenterol Hepatol. 2009 Nov; 6(11):623.
Score: 0.010
-
Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1570-82.
Score: 0.010
-
The wrong end of the scope. Nat Rev Gastroenterol Hepatol. 2009 Oct; 6(10):559.
Score: 0.010
-
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3.
Score: 0.010
-
Don't miss the forest for the trees. Inflamm Bowel Dis. 2009 Sep; 15(9):1397-8.
Score: 0.010
-
Exploring the controversial themes of IBD. Inflamm Bowel Dis. 2009 Sep; 15 Suppl 1:S1-10.
Score: 0.010
-
Addicted to acid suppression. Nat Rev Gastroenterol Hepatol. 2009 Sep; 6(9):497.
Score: 0.010
-
Quid pro quo and the pharmascolds. Nat Rev Gastroenterol Hepatol. 2009 Aug; 6(8):437.
Score: 0.010
-
The burdens of digestive diseases. Nat Rev Gastroenterol Hepatol. 2009 Jul; 6(7):377.
Score: 0.010
-
Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48.
Score: 0.010
-
Keep your cool: burn calories. Nat Rev Gastroenterol Hepatol. 2009 Jun; 6(6):315.
Score: 0.010
-
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
Score: 0.010
-
More food for thought. Nat Rev Gastroenterol Hepatol. 2009 May; 6(5):253.
Score: 0.010
-
Outsourcing clinical trials. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):191.
Score: 0.010
-
Tyler, Faecalibacterium and biodiversity. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb; 6(2):63.
Score: 0.010
-
Sarcopenia and the elusive fountain of youth. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):1.
Score: 0.010
-
Sitting on the fence. Nat Clin Pract Gastroenterol Hepatol. 2008 Dec; 5(12):655.
Score: 0.010
-
Conflicts. Nat Clin Pract Gastroenterol Hepatol. 2008 Nov; 5(11):589.
Score: 0.010
-
The ethics of phase I trials of biologic agents. Nat Clin Pract Gastroenterol Hepatol. 2008 Oct; 5(10):533.
Score: 0.009
-
Modifying risk factors: do the means justify the ends? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):475.
Score: 0.009
-
Mea culpa. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):409.
Score: 0.009
-
Jet lag: life in the fast (and feast) lane. Nat Clin Pract Gastroenterol Hepatol. 2008 Jul; 5(7):349.
Score: 0.009
-
Deadlines. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):291.
Score: 0.009
-
Flat polyps depress gastroenterologists. Nat Clin Pract Gastroenterol Hepatol. 2008 May; 5(5):231.
Score: 0.009
-
An ounce of prevention. Nat Clin Pract Nephrol. 2008 Apr; 4(4):173.
Score: 0.009
-
Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008 Mar; 27 Suppl 1:15-21.
Score: 0.009
-
Experienced pleasantness. Nat Clin Pract Gastroenterol Hepatol. 2008 Mar; 5(3):119.
Score: 0.009
-
Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59.
Score: 0.009
-
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
Score: 0.009
-
Subgroups. Nat Clin Pract Gastroenterol Hepatol. 2008 Jan; 5(1):1.
Score: 0.009
-
The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord. 2008; 8(1):15-20.
Score: 0.009
-
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
Score: 0.009
-
My favorite topic...health. Nat Clin Pract Gastroenterol Hepatol. 2007 Dec; 4(12):641.
Score: 0.009
-
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34.
Score: 0.009
-
An ounce of prevention. Nat Clin Pract Gastroenterol Hepatol. 2007 Nov; 4(11):583.
Score: 0.009
-
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
Score: 0.009
-
More likely than not. Nat Clin Pract Gastroenterol Hepatol. 2007 Sep; 4(9):469.
Score: 0.009
-
Parallel universes. Nat Clin Pract Gastroenterol Hepatol. 2007 Aug; 4(8):411.
Score: 0.009
-
Where do our priorities lie? Nat Clin Pract Gastroenterol Hepatol. 2007 Jul; 4(7):353.
Score: 0.009
-
Moving ahead or falling behind? Nat Clin Pract Gastroenterol Hepatol. 2007 Jun; 4(6):295.
Score: 0.009
-
Uncertainty. Nat Clin Pract Gastroenterol Hepatol. 2007 May; 4(5):235.
Score: 0.009
-
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007 May; 23(5):1033-43.
Score: 0.009
-
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
Score: 0.009
-
Back to basics: food for thought--and nutrition. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):175.
Score: 0.009
-
Balancing drug availability and patient safety. Nat Clin Pract Gastroenterol Hepatol. 2007 Mar; 4(3):117.
Score: 0.008
-
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802.
Score: 0.008
-
Stepping up to good health. Nat Clin Pract Gastroenterol Hepatol. 2007 Feb; 4(2):59.
Score: 0.008
-
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14.
Score: 0.008
-
European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3.
Score: 0.008
-
Fragile egos. Nat Clin Pract Gastroenterol Hepatol. 2007 Jan; 4(1):1.
Score: 0.008
-
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11.
Score: 0.008
-
Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2.
Score: 0.008
-
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22.
Score: 0.008
-
The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S1-2.
Score: 0.008
-
Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10.
Score: 0.008
-
General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
Score: 0.008
-
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
Score: 0.008
-
Weighing in on obesity--a sample size issue? Nat Clin Pract Gastroenterol Hepatol. 2006 Nov; 3(11):593.
Score: 0.008
-
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
Score: 0.008
-
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
Score: 0.008
-
Fertile ground. Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):533.
Score: 0.008
-
"Hit me with your best shot... Fire away!". Nat Clin Pract Gastroenterol Hepatol. 2006 Sep; 3(9):473.
Score: 0.008
-
Safety first: messages from Digestive Disease Week 2006. Nat Clin Pract Gastroenterol Hepatol. 2006 Aug; 3(8):415.
Score: 0.008
-
It's right under our nose: homage to the Nobel Prize and other stories! Nat Clin Pract Gastroenterol Hepatol. 2006 Jul; 3(7):355.
Score: 0.008
-
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9.
Score: 0.008
-
Steroids as recreational drugs. Nat Clin Pract Gastroenterol Hepatol. 2006 Jun; 3(6):295.
Score: 0.008
-
New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis. 2006 May; 8 Suppl 1:20-4.
Score: 0.008
-
Evidence-based medicine: applied science? Nat Clin Pract Gastroenterol Hepatol. 2006 Apr; 3(4):177.
Score: 0.008
-
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464.
Score: 0.008
-
Procreation without recreation. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):117.
Score: 0.008
-
The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59.
Score: 0.008
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
Score: 0.008
-
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S3-9.
Score: 0.008
-
Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89.
Score: 0.008
-
I've sold my sport-utility vehicle. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec; 2(12):551.
Score: 0.008
-
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
Score: 0.008
-
Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493.
Score: 0.008
-
Another one bites the dust. Nat Clin Pract Gastroenterol Hepatol. 2005 Oct; 2(10):435.
Score: 0.008
-
Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology. 2005 Oct; 129(4):1358-9; author reply 1359.
Score: 0.008
-
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724.
Score: 0.008
-
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 Sep 01; 22(5):441-6.
Score: 0.008
-
Supplemental evidence. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep; 2(9):375.
Score: 0.008
-
Novel potential perils of volunteering for clinical trials. Nat Clin Pract Gastroenterol Hepatol. 2005 Aug; 2(8):337.
Score: 0.008
-
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9.
Score: 0.008
-
Institutional review boards: the cost to academic medical centers. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):287.
Score: 0.008
-
The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12.
Score: 0.008
-
Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6.
Score: 0.008
-
Obesity and visceral fat: a growing inflammatory disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):245.
Score: 0.008
-
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 Nov; 169(6):1282-1293.
Score: 0.007
-
Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5.
Score: 0.007
-
Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):199.
Score: 0.007
-
The 'upside' of travelers' diarrhea: a personal case report. Nat Clin Pract Gastroenterol Hepatol. 2005 Apr; 2(4):161.
Score: 0.007
-
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71.
Score: 0.007
-
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.
Score: 0.007
-
The whole is greater than the sum. Nat Clin Pract Gastroenterol Hepatol. 2005 Feb; 2(2):59.
Score: 0.007
-
Conflicts of interest. Nat Clin Pract Gastroenterol Hepatol. 2005 Jan; 2(1):1.
Score: 0.007
-
Should you "just say 'no'"? Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):59.
Score: 0.007
-
Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
Score: 0.007
-
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J Immunother Cancer. 2024 Nov 14; 12(11).
Score: 0.007
-
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflamm Bowel Dis. 2024 11 04; 30(11):2064-2075.
Score: 0.007
-
Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis. J Crohns Colitis. 2024 Nov 04; 18(11):1863-1869.
Score: 0.007
-
COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov; 5(11):1192-7.
Score: 0.007
-
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2004 Nov; 1(1):26-31.
Score: 0.007
-
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1512-1524.
Score: 0.007
-
Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5.
Score: 0.007
-
Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:97-101.
Score: 0.007
-
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
Score: 0.007
-
HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6.
Score: 0.007
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
Score: 0.007
-
Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):303-17, ix-x.
Score: 0.007
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719.
Score: 0.007
-
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88.
Score: 0.007
-
Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004 May; 126(6):1582-92.
Score: 0.007
-
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23; 18(4):493-505.
Score: 0.007
-
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054.
Score: 0.007
-
Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer. J Clin Invest. 2024 Apr 01; 134(7).
Score: 0.007
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13.
Score: 0.007
-
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6.
Score: 0.007
-
Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
Score: 0.007
-
Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
Score: 0.007
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
Score: 0.007
-
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
Score: 0.007
-
Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23.
Score: 0.007
-
Benign solitary cecal ulcer: a case report and review of the literature. Dig Dis Sci. 2003 Nov; 48(11):2207-12.
Score: 0.007
-
Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent-A case-control study. Indian J Gastroenterol. 2024 02; 43(1):244-253.
Score: 0.007
-
Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10.
Score: 0.007
-
The importance of predicting patient responses to monoclonal antibodies for Crohn's disease. Expert Opin Biol Ther. 2023 Jul-Dec; 23(10):941-949.
Score: 0.007
-
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2.
Score: 0.007
-
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296.
Score: 0.007
-
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64.
Score: 0.007
-
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14.
Score: 0.007
-
Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
Score: 0.007
-
A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8.
Score: 0.006
-
Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol. 2003 Mar; 98(3):697-8.
Score: 0.006
-
Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7.
Score: 0.006
-
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42.
Score: 0.006
-
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003 Jan; 98(1):215-6.
Score: 0.006
-
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43.
Score: 0.006
-
The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
Score: 0.006
-
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72.
Score: 0.006
-
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 04; 21(4):878-890.
Score: 0.006
-
Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflamm Bowel Dis. 2022 10 03; 28(10):1603-1606.
Score: 0.006
-
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
Score: 0.006
-
New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3.
Score: 0.006
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Score: 0.006
-
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
Score: 0.006
-
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
Score: 0.006
-
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. Am J Gastroenterol. 2022 08 01; 117(8):1288-1295.
Score: 0.006
-
Medical treatment of Crohn's disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):167-84, x.
Score: 0.006
-
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890.
Score: 0.006
-
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99.
Score: 0.006
-
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
Score: 0.006
-
Can cyclosporine go it alone in severe ulcerative colitis? Curr Gastroenterol Rep. 2001 Dec; 3(6):455-6.
Score: 0.006
-
The smoke is clearing in Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):456-7.
Score: 0.006
-
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.
Score: 0.006
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
Score: 0.006
-
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
Score: 0.006
-
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291.
Score: 0.006
-
Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. J Clin Psychol Med Settings. 2022 09; 29(3):596-607.
Score: 0.006
-
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.
Score: 0.006
-
Crohn's disease therapy: step up or top down therapy. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):189-90.
Score: 0.006
-
Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2.
Score: 0.006
-
Neutrophils Alter DNA Repair Landscape to Impact Survival and Shape Distinct Therapeutic Phenotypes of Colorectal Cancer. Gastroenterology. 2021 07; 161(1):225-238.e15.
Score: 0.006
-
Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43.
Score: 0.006
-
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.
Score: 0.006
-
Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318.
Score: 0.006
-
Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA. Rev Gastroenterol Disord. 2001; 1(2):100-10.
Score: 0.006
-
Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76.
Score: 0.006
-
Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
Score: 0.005
-
Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48.
Score: 0.005
-
Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
Score: 0.005
-
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
Score: 0.005
-
The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology. 2020 09; 72(3):1127-1138.
Score: 0.005
-
Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
Score: 0.005
-
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000 Jul; 95(7):1749-54.
Score: 0.005
-
Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. Int J Cancer. 2020 11 15; 147(10):2735-2742.
Score: 0.005
-
Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 2000 May; 95(5):1139-46.
Score: 0.005
-
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
Score: 0.005
-
Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated? Gastrointest Endosc. 2000 Feb; 51(2):240-2.
Score: 0.005
-
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
Score: 0.005
-
Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9.
Score: 0.005
-
Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep; 13 Suppl 4:16-22; discussion 38.
Score: 0.005
-
Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94.
Score: 0.005
-
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92.
Score: 0.005
-
Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321.
Score: 0.005
-
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33.
Score: 0.005
-
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455.
Score: 0.005
-
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10.
Score: 0.005
-
Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019 02 01; 129(2):712-726.
Score: 0.005
-
Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2019 05; 75(5):846-852.
Score: 0.005
-
No butts about it: put the fire out by lighting up. Inflamm Bowel Dis. 1998 Nov; 4(4):326; discussion 327.
Score: 0.005
-
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72.
Score: 0.005
-
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
Score: 0.005
-
Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology. 1998 Sep; 115(3):525-32.
Score: 0.005
-
Non-Hodgkin's lymphoma presenting nine years after ileal-pouch ileoanal anastomosis for ulcerative colitis. Am J Gastroenterol. 1998 Sep; 93(9):1589-90.
Score: 0.005
-
Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
Score: 0.005
-
Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. Inflamm Bowel Dis. 2018 08 16; 24(9):2001-2006.
Score: 0.005
-
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77.
Score: 0.005
-
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
Score: 0.005
-
Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
Score: 0.005
-
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998 May; 4(2):79-83.
Score: 0.005
-
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
Score: 0.005
-
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
Score: 0.005
-
How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Inflamm Bowel Dis. 1998 Feb; 4(1):70; discussion 73.
Score: 0.005
-
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671.
Score: 0.005
-
Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
Score: 0.004
-
Medical management of perianal Crohn's disease. Semin Gastrointest Dis. 1998 Jan; 9(1):10-4.
Score: 0.004
-
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
Score: 0.004
-
Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997 Sep; 92(9):1424-8.
Score: 0.004
-
miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
Score: 0.004
-
The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis. 2017 04; 23(4):561-569.
Score: 0.004
-
Management of Crohn's disease in adults. Am J Gastroenterol. 1997 Apr; 92(4):559-66.
Score: 0.004
-
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
Score: 0.004
-
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960.
Score: 0.004
-
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723.
Score: 0.004
-
Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254.
Score: 0.004
-
Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. Am J Med. 1996 Sep; 101(3):323-5.
Score: 0.004
-
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
Score: 0.004
-
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62.
Score: 0.004
-
Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62.
Score: 0.004
-
pANCA and classification resistance in ulcerative colitis. Mayo Clin Proc. 1996 May; 71(5):517-8.
Score: 0.004
-
Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis. 2016 May; 22(5):1168-83.
Score: 0.004
-
Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May; 18(5):21.
Score: 0.004
-
Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8.
Score: 0.004
-
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578.
Score: 0.004
-
Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
Score: 0.004
-
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9.
Score: 0.004
-
Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther. 1996 Feb; 10(1):1-22.
Score: 0.004
-
Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2.
Score: 0.004
-
New therapeutic approaches. Gastroenterol Clin North Am. 1995 Sep; 24(3):523-40.
Score: 0.004
-
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
Score: 0.004
-
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16.
Score: 0.004
-
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17.
Score: 0.004
-
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40.
Score: 0.004
-
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16.
Score: 0.004
-
Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut. 1995 May; 36(5):715-7.
Score: 0.004
-
The management of ulcerative colitis. Annu Rev Med. 1995; 46:497-505.
Score: 0.004
-
Medical therapy of inflammatory bowel disease. Med Clin North Am. 1994 Nov; 78(6):1413-26.
Score: 0.004
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
Score: 0.004
-
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90.
Score: 0.004
-
In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47.
Score: 0.004
-
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4.
Score: 0.004
-
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30; 330(26):1841-5.
Score: 0.004
-
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
Score: 0.003
-
Radiation exposure in gastroenterology: improving patient and staff protection. Am J Gastroenterol. 2014 Aug; 109(8):1180-94.
Score: 0.003
-
Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc. 1994 May; 69(5):425-9.
Score: 0.003
-
AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis. 2014 May; 20(5):872-81.
Score: 0.003
-
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35.
Score: 0.003
-
Nicotine for colitis--the smoke has not yet cleared. N Engl J Med. 1994 Mar 24; 330(12):856-7.
Score: 0.003
-
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.
Score: 0.003
-
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
Score: 0.003
-
Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2.
Score: 0.003
-
Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51.
Score: 0.003
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710.
Score: 0.003
-
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21.
Score: 0.003
-
Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96.
Score: 0.003
-
Medical therapy of ulcerative colitis. Lancet. 1993 Aug 14; 342(8868):412-7.
Score: 0.003
-
Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993 Aug; 88(8):1174-8.
Score: 0.003
-
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug; 88(8):1188-97.
Score: 0.003
-
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95.
Score: 0.003
-
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
Score: 0.003
-
Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993 May; 88(5):646-9.
Score: 0.003
-
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9.
Score: 0.003
-
Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. Inflamm Bowel Dis. 2013 Mar; 19(3):461-70.
Score: 0.003
-
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
Score: 0.003
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.003
-
Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60.
Score: 0.003
-
Crohn's disease. Curr Probl Surg. 1993 Feb; 30(2):173-265.
Score: 0.003
-
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
Score: 0.003
-
Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
Score: 0.003
-
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28.
Score: 0.003
-
Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med. 1992 Aug 13; 327(7):497-8.
Score: 0.003
-
Primary sclerosing cholangitis and ulcerative colitis: potential cofactors in the dysplasia sequence. Gastroenterology. 1992 Jun; 102(6):2161-2.
Score: 0.003
-
Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colon. PLoS One. 2012; 7(2):e32545.
Score: 0.003
-
Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
Score: 0.003
-
What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7.
Score: 0.003
-
Relief of functional bowel obstruction. JAMA. 1992 Jan 15; 267(3):414.
Score: 0.003
-
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
Score: 0.003
-
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9.
Score: 0.003
-
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42.
Score: 0.003
-
Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology. 1991 Oct; 101(4):1130-1.
Score: 0.003
-
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56.
Score: 0.003
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
Score: 0.003
-
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
Score: 0.003
-
The absence of an association between oral contraceptive use and ulcerative colitis in patients. Gastroenterology. 1991 Jun; 100(6):1784.
Score: 0.003
-
miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
Score: 0.003
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
Score: 0.003
-
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11.
Score: 0.003
-
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
Score: 0.003
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.003
-
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
Score: 0.003
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
Score: 0.003
-
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
Score: 0.003
-
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93.
Score: 0.003
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
Score: 0.003
-
Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7.
Score: 0.003
-
Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology. 1990 Oct; 99(4):1032-6.
Score: 0.003
-
Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep; 85(9):1083-7.
Score: 0.003
-
Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
Score: 0.003
-
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol. 2010 Jun 15; 184(12):7001-9.
Score: 0.003
-
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
Score: 0.003
-
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.
Score: 0.003
-
Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990 Mar; 35(3):349-52.
Score: 0.003
-
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
Score: 0.003
-
The role of mesalazine in Crohn's disease. Scand J Gastroenterol Suppl. 1990; 172:56-9.
Score: 0.003
-
Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106.
Score: 0.003
-
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7.
Score: 0.003
-
Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci. 1989 Oct; 34(10):1536-41.
Score: 0.003
-
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
Score: 0.003
-
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug; 97(2):255-9.
Score: 0.003
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
Score: 0.003
-
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug; 104(8):2089-96.
Score: 0.002
-
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36.
Score: 0.002
-
5-ASA enema therapy. Neth J Med. 1989 Jun; 35 Suppl 1:S11-20.
Score: 0.002
-
Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis. Int J Cancer. 1989 May 15; 43(5):810-5.
Score: 0.002
-
Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci. 1989 May; 34(5):741-6.
Score: 0.002
-
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22.
Score: 0.002
-
Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484.
Score: 0.002
-
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31.
Score: 0.002
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60.
Score: 0.002
-
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9.
Score: 0.002
-
Smoking and inflammatory bowel disease in families. Am J Gastroenterol. 1988 Apr; 83(4):407-9.
Score: 0.002
-
Fecal incontinence in the elderly. Hosp Pract (Off Ed). 1988 Mar 30; 23(3A):105-8, 111-2.
Score: 0.002
-
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar; 134(3):688-95.
Score: 0.002
-
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5.
Score: 0.002
-
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
Score: 0.002
-
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22.
Score: 0.002
-
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
Score: 0.002
-
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39.
Score: 0.002
-
Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9.
Score: 0.002
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
Score: 0.002
-
Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med. 2007 Apr; 33(2):207-12.
Score: 0.002
-
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9.
Score: 0.002
-
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86.
Score: 0.002
-
Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology. 1986 Dec; 91(6):1396-400.
Score: 0.002
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
Score: 0.002
-
Clostridium difficile culture-positive toxin-negative diarrhea. Am J Gastroenterol. 1986 Oct; 81(10):940-3.
Score: 0.002
-
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
Score: 0.002
-
Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23.
Score: 0.002
-
Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology. 1986 Apr; 90(4):1039-41.
Score: 0.002
-
Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol. 2006 Mar; 101(3):572-80.
Score: 0.002
-
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76.
Score: 0.002
-
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
Score: 0.002
-
Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8.
Score: 0.002
-
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7.
Score: 0.002
-
Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):308-15.
Score: 0.002
-
Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
Score: 0.002
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
Score: 0.002
-
Crohn's disease. The problem and its management. Hosp Pract (Off Ed). 1984 Jul; 19(7):121-32, 135-6, 141-2.
Score: 0.002
-
Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
Score: 0.002
-
Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
Score: 0.002
-
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98.
Score: 0.002
-
Selected individual therapeutic problems in inflammatory bowel disease. Am J Gastroenterol. 1984 May; 79(5):368-75.
Score: 0.002
-
AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30.
Score: 0.002
-
Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9.
Score: 0.002
-
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8.
Score: 0.002
-
Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet. 2002 Oct 01; 11(21):2599-606.
Score: 0.002
-
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002 Jul; 97(7):1748-54.
Score: 0.002
-
Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982 Jun; 27(6):545-8.
Score: 0.002
-
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30.
Score: 0.001
-
Best of DDW 2002. Highlights from the 2002 Digestive Disease Week. May 19-22, 2002, San Francisco, CA. Rev Gastroenterol Disord. 2002; 2(3):126-41.
Score: 0.001
-
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6.
Score: 0.001
-
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94.
Score: 0.001
-
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May 31; 411(6837):603-6.
Score: 0.001
-
Infectious complications associated with hairy cell leukemia. J Infect Dis. 1981 May; 143(5):639-43.
Score: 0.001
-
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8.
Score: 0.001
-
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8.
Score: 0.001
-
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44.
Score: 0.001
-
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72.
Score: 0.001
-
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1473-82.
Score: 0.001
-
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000 Dec; 119(6):1483-90.
Score: 0.001
-
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000 Nov; 95(11):3150-6.
Score: 0.001
-
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg. 2000 Sep; 232(3):401-8.
Score: 0.001
-
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 01; 342(22):1627-32.
Score: 0.001
-
Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet. 2000 May 22; 9(9):1425-32.
Score: 0.001
-
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15.
Score: 0.001
-
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9.
Score: 0.001
-
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35.
Score: 0.001
-
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999 Jul; 117(1):58-64.
Score: 0.001
-
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405.
Score: 0.001
-
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology. 1998 Nov; 115(5):1056-61.
Score: 0.001
-
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7502-7.
Score: 0.001
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
Score: 0.001
-
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. 1997 Apr; 40(4):485-91.
Score: 0.001
-
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 1997 Mar; 112(3):725-32.
Score: 0.001
-
A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. Exp Hematol. 1996 Jun; 24(7):823-8.
Score: 0.001
-
Diphenhydramine provides relief of cyclophosphamide-related symptoms. Oncol Nurs Forum. 1996 Apr; 23(3):542.
Score: 0.001
-
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996 Feb; 17(2):157-62.
Score: 0.001
-
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum. 1995 Dec; 38(12):1241-5.
Score: 0.001
-
Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant. 1995 Jul; 16(1):163-8.
Score: 0.001
-
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5.
Score: 0.001
-
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304.
Score: 0.001
-
International forum on ulcerative colitis. Risk selection aspects of ulcerative colitis. J Insur Med. 1995; 27(2):167-80.
Score: 0.001
-
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994 Feb; 8(1):27-34.
Score: 0.001
-
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301.
Score: 0.001
-
Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. 1993 Mar; 88(3):356-9.
Score: 0.001
-
Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991 Sep; 32(9):1071-5.
Score: 0.001
-
Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci. 1990 Jul; 35(7):827-32.
Score: 0.001
-
Cigarette smoking in Crohn's disease. Am J Gastroenterol. 1989 Jan; 84(1):31-3.
Score: 0.001
-
Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med. 1988 Feb; 108(2):274-8.
Score: 0.001
-
Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology. 1985 Jan-Feb; 5(1):79-84.
Score: 0.000
-
Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology. 1983 Dec; 85(6):1313-8.
Score: 0.000
-
Disseminated Trichosporon beigelii (cutaneum). Cancer. 1981 Nov 01; 48(9):2107-11.
Score: 0.000